Paclitaxel, carboplatin, and trastuzumab in a neo-adjuvant regimen for HER2-positive breast cancer

Breast Journal

Volumn 19, Issue 4, 2013, Pages 419-426

  Sonke, Gabe S ^a   Mandjes, Ingrid A ^a   Holtkamp, Marjo J ^a   Schot, Margaret ^a   Van Werkhoven, Erik ^a   Wesseling, Jelle ^a   Vrancken Peeters, Marie Jeanne ^a   Rodenhuis, Sjoerd ^a   Linn, Sabine C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

breast cancer; chemotherapy; neo adjuvant; trastuzumab

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; ANEMIA; ARTICLE; BONE MARROW TOXICITY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER STAGING; CARDIOTOXICITY; DISTANT METASTASIS; DRUG DOSE REGIMEN; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; HEART LEFT VENTRICLE FAILURE; HUMAN; IMMUNOHISTOCHEMISTRY; LEUKOPENIA; LOADING DRUG DOSE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NAUSEA; NEUROPATHY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TREATMENT RESPONSE;

BREAST CANCER; CHEMOTHERAPY; NEO-ADJUVANT; TRASTUZUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEUTROPENIA; PACLITAXEL; RECEPTOR, ERBB-2; REMISSION INDUCTION; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 84879786686     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12124     Document Type: Article

References (39)

1. Slamon DJ, Godolphin W, Jones LA, et al,. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244: 707-12.
2. Carter P, Presta L, Gorman CM, et al,. Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-9.
3. Slamon DJ, Leyland-Jones B, Shak S, et al,. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-92.
4. Marty M, Cognetti F, Maraninchi D, et al,. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 2005; 23: 4265-74.
5. Romond EH, Perez EA, Bryant J, et al,. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353: 1673-84.
6. Piccart-Gebhart M, Procter M, Leyland-Jones B, et al,. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005; 353: 1659-72.
7. Buzdar AU, Ibrahim NK, Francis D, et al,. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005; 23: 3676-85.
8. Gianni L, Eiermann W, Semiglazov V, et al,. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010; 375: 377-84.
9. Untch M, Rezai M, Loibl S, et al,. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol 2010; 28: 2024-31.
10. Pegram M, Konecny G, O'Callaghan C, Beryt M, Pietras R, Slamon D,. Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer. J Natl Cancer Inst 2004; 96: 739-49.
11. Perez EA,. Carboplatin in combination therapy for metastatic breast cancer. Oncologist 2004; 9: 518-27.
12. Burris H, Yardley D, Jones S, et al,. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 2004; 22: 1621-9.
13. Robert N, Leyland-Jones B, Asmar L, et al,. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006; 24: 2786-92.
14. Perez EA, Suman VJ, Rowland KM, et al,. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 2005; 6: 425-32.
15. Ruiz M, Salvador J, Bayo J, et al,. Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 2008; 62: 1085-90.
16. Slamon DJ, Eiermann W, Robert N, et al,. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011; 365: 1273-83.
17. Coudert BP, Largillier R, Arnould L, et al,. Multicenter phase II trial of neoadjuvant therapy with trastuzumab, docetaxel, and carboplatin for human epidermal growth factor receptor-2-overexpressing stage II or III breast cancer: results of the GETN(A)-1 trial. J Clin Oncol 2007; 25: 2678-84.
18. Sparano J, Wang M, Martino S, et al,. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008; 358: 1663-71.
19. Mehta RS, Schubbert T, Kong K,. Trastuzumab in inflammatory breast cancer. Ann Oncol 2008; 19: 1815-7.
20. Rodenhuis S, Mandjes IA, Wesseling J, et al,. A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. Ann Oncol 2010; 21: 481-7.
21. Burstein H, Harris L, Gelman R, et al,. Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/ cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 2003; 21: 46-53.
22. Wenzel C, Hussian D, Bartsch R, et al,. Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study. J Cancer Res Clin Oncol 2004; 130: 400-4.
23. Hurley J, Doliny P, Reis I, et al,. Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer. J Clin Oncol 2006; 24: 1831-8.
24. Kelly H, Kimmick G, Dees EC, et al,. Response and cardiac toxicity of trastuzumab given in conjunction with weekly paclitaxel after doxorubicin/cyclophosphamide. Clin Breast Cancer 2006; 7: 237-43.
25. Limentani S, Brufsky A, Erban J, Jahanzeb M, Lewis D,. Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal growth factor receptor 2-overexpressing locally advanced breast cancer. J Clin Oncol 2007; 25: 1232-8.
26. Paluch-Shimon S, Wolf I, Goldberg H, et al,. High efficacy of pre-operative trastuzumab combined with paclitaxel following doxorubicin & cyclophosphamide in operable breast cancer. Acta Oncol 2008; 47: 1564-9.
27. Sikov W, Dizon D, Strenger R, et al,. Frequent pathologic complete responses in aggressive stages II to III breast cancers with every-4-week carboplatin and weekly paclitaxel with or without trastuzumab: a brown university oncology group study. J Clin Oncol 2009; 27: 4693-700.
28. Pierga J, Delaloge S, Espié M, et al,. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. Breast Cancer Res Treat 2010; 122: 429-37.
29. Sanchez-Munoz A, Duenas-Garcia R, Jaen-Morago A, et al,. Is it possible to increase pCR in the neoadjuvant treatment with a dose-dense/sequential combination? Results from a phase II trial combining epirubicin and cyclophosphamide followed by paclitaxel and gemcitabine ± trastuzumab in stage II and III breast cancer patients. Am J Clin Oncol 2010; 33: 432-7.
30. Anton A, Ruiz A, Plazaola A, et al,. Phase II clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neoadjuvant treatment in stages II and IIIA HER2-overexpressing breast cancer patients. GEICAM 2003-03 study. Ann Oncol 2011; 22: 74-9.
31. Wildiers H, Neven P, Christiaens MR, et al,. Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer. Ann Oncol 2011; 22: 588-94.
32. Buzdar AU, Valero V, Ibrahim NK, et al,. Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized study population and data of additional patients treated with the same regimen. Clin Cancer Res 2007; 13: 228-33.
33. Kuroi K, Toi M, Tsuda H, Kurosumi M, Akiyama F,. Issues in the assessment of the pathologic effect of primary systemic therapy for breast cancer. Breast Cancer 2006; 13: 38-48.
34. Chang HR,. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer. Cancer 2010; 116: 2856-67.
35. Bartlett J, Munro A, Dunn J, et al,. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol 2010; 11: 266-74.
36. Agus DB, Akita RW, Fox WD, et al,. Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. Cancer Cell 2002; 2: 127-37.
37. Nahta R, Yuan LXH, Zhang B, Kobayashi R, Esteva FJ,. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65: 11118-28.
38. Baselga J, Bradbury I, Eidtmann H, et al,. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet 2012; 379: 633-40.
39. Gianni L, Pienkowski T, Im Y, et al,. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol 2012; 13: 25-32.